NCT07223424 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07223424
Title	Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)
Acronym	PSI-Immune
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Diwakar Davar
Indications	colorectal cancer renal cell carcinoma lung non-small cell carcinoma gastric adenocarcinoma Advanced Solid Tumor Merkel cell carcinoma endometrial carcinoma esophagus adenocarcinoma melanoma transitional cell carcinoma skin squamous cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer esophageal cancer cervical cancer hepatocellular carcinoma
Therapies	Pembrolizumab Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
UPMC Hillman Cancer Center	RECRUITING	Pittsburgh	Pennsylvania	15232	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07223424Clinical Trial Detail